Unknown

Dataset Information

0

A phase 1 study of 131I-CLR1404 in patients with relapsed or refractory advanced solid tumors: dosimetry, biodistribution, pharmacokinetics, and safety.


ABSTRACT: (131)I-CLR1404 is a small molecule that combines a tumor-targeting moiety with a therapeutic radioisotope. The primary aim of this phase 1 study was to determine the administered radioactivity expected to deliver 400 mSv to the bone marrow. The secondary aims were to determine the pharmacokinetic (PK) and safety profiles of (131)I-CLR1404.Eight subjects with refractory or relapsed advanced solid tumors were treated with a single injection of 370 MBq of (131)I-CLR1404. Whole body planar nuclear medicine scans were performed at 15-35 minutes, 4-6, 18-24, 48, 72, 144 hours, and 14 days post injection. Optional single photon emission computed tomography imaging was performed on two patients 6 days post injection. Clinical laboratory parameters were evaluated in blood and urine. Plasma PK was evaluated on (127)I-CLR1404 mass measurements. To evaluate renal clearance of (131)I-CLR1404, urine was collected for 14 days post injection. Absorbed dose estimates for target organs were determined using the RADAR method with OLINDA/EXM software.Single administrations of 370 MBq of (131)I-CLR1404 were well tolerated by all subjects. No severe adverse events were reported and no adverse event was dose-limiting. Plasma (127)I-CLR1404 concentrations declined in a bi-exponential manner with a mean t½ value of 822 hours. Mean Cmax and AUC(0-t) values were 72.2 ng/mL and 15753 ng • hr/mL, respectively. An administered activity of approximately 740 MBq is predicted to deliver 400 mSv to marrow.Preliminary data suggest that (131)I-CLR1404 is well tolerated and may have unique potential as an anti-cancer agent.ClinicalTrials.gov NCT00925275.

SUBMITTER: Grudzinski JJ 

PROVIDER: S-EPMC4234270 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature

altmetric image

Publications

A phase 1 study of 131I-CLR1404 in patients with relapsed or refractory advanced solid tumors: dosimetry, biodistribution, pharmacokinetics, and safety.

Grudzinski Joseph J JJ   Titz Benjamin B   Kozak Kevin K   Clarke William W   Allen Ernest E   Trembath LisaAnn L   Stabin Michael M   Marshall John J   Cho Steve Y SY   Wong Terence Z TZ   Mortimer Joanne J   Weichert Jamey P JP  

PloS one 20141117 11


<h4>Introduction</h4>(131)I-CLR1404 is a small molecule that combines a tumor-targeting moiety with a therapeutic radioisotope. The primary aim of this phase 1 study was to determine the administered radioactivity expected to deliver 400 mSv to the bone marrow. The secondary aims were to determine the pharmacokinetic (PK) and safety profiles of (131)I-CLR1404.<h4>Methods</h4>Eight subjects with refractory or relapsed advanced solid tumors were treated with a single injection of 370 MBq of (131)I  ...[more]

Similar Datasets

| S-EPMC7097682 | biostudies-literature
| S-EPMC10668247 | biostudies-literature
| S-EPMC5858550 | biostudies-literature
| S-EPMC3579428 | biostudies-literature
| S-EPMC8465706 | biostudies-literature
| S-EPMC8342607 | biostudies-literature
| S-EPMC9339467 | biostudies-literature
| S-EPMC4470833 | biostudies-literature
| S-EPMC5750520 | biostudies-literature
| S-EPMC3553417 | biostudies-literature